World News

This agreement also grants Boston Scientific an exclusive option to acquire the TAVR programme, subject to additional payments and to clinical and regulatory milestones.

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

The antiviral drug was originally designed to treat influenza but has also attracted attention for its potential activity against other RNA viruses.

Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.

The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.

The company will present its newly CE-marked AI contouring solution at the annual congress of the European Society for Radiotherapy and Oncology in Stockholm.

Through this acquisition, the company strengthens its ability to support cell therapy developers with integrated manufacturing, processing, and cryopreservation services under a unified platform.

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.